イワモト タカユキ
Takayuki Iwamoto
岩本 高行 所属 川崎医科大学 医学部 臨床医学 乳腺甲状腺外科学 職種 講師 |
|
論文種別 | 原著 |
言語種別 | 英語 |
査読の有無 | 査読あり |
表題 | Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. |
掲載誌名 | 正式名:Breast cancer research and treatment 略 称:Breast Cancer Res Treat ISSNコード:15737217/01676806 |
掲載区分 | 国外 |
巻・号・頁 | 125(3),pp.785-95 |
著者・共著者 | Takayuki Iwamoto, Giampaolo Bianchini, Yuan Qi, Massimo Cristofanilli, Anthony Lucci, Wendy A Woodward, James M Reuben, Junji Matsuoka, Yun Gong, Savitri Krishnamurthy, Vicente Valero, Gabriel N Hortobagyi, Fredika Robertson, W Fraser Symmans, Lajos Pusztai, Naoto T Ueno |
担当区分 | 筆頭著者 |
発行年月 | 2011/02 |
概要 | The goal of this study was to determine whether gene expression differences exist between inflammatory breast cancers (IBC) and T stage-matched non-IBC patients stratified by hormone receptor and HER2 status. We used Affymetrix GeneChips to analyze 82 tumor samples (25 T4d patients, and 57 T4a-c patients) of newly diagnosed breast cancers. Genes that were differentially expressed between the IBC and non-IBC specimens were identified using the t test, and differential expression of gene sets was assessed using gene set analysis. Three distinct clinical subtypes of IBC and non-IBC were compared: ER-positive/HER2-normal, HER2-amplified, and ER-negative/HER2-normal. When we compared expression data from all IBC with all non-IBC, we found no significant differences after adjusting for multiple testing. When IBC and non-IBC tumors were compared by clinical subtype, however, significant differences emerged. Complement and immune system-related pathways were overexpressed in ER-positive/HER2-normal IBC. Protein translation and mTOR signaling were overexpressed in HER2-amplified IBC. Apoptosis-, neural-, and lipid metabolism-related pathways were overexpressed in ER-negative/HER2-normal IBC compared with non-IBC of the same receptor phenotype. In this T stage-matched case-control study, the survival curves of patients with IBC and non-IBC were similar for all three clinical subtypes. IBC tumors can be divided into molecular and clinical subtypes similar to those of non-IBC. Clinical subtypes of IBC show molecular differences compared with similar subtypes of non-IBC. |
DOI | 10.1007/s10549-010-1280-6 |
PMID | 21153052 |